Genzyme rare-disease drug gets priority label

Share this article:

The FDA granted priority review status to Genzyme's experimental, all-oral Gaucher's disease treatment Cerdelga (eliglustat).

The FDA's priority label means the regulator will decide for or against the twice-a-day pill within six months.

The Sanofi subsidiary said in a statement that the 400-patient clinical trial supporting the filing is the largest ever conducted for Gaucher's disease.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.